Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.
Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...
About the Role The Multiple Myeloma Nurse Coordinator will facilitate evidence based individualized, coordinated care for patients with haematological malignancies across the cancer trajectory. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results